Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside

HCV Polymerase Inhibitor Being Presented at AASLD

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of HCV. These results are being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in San Francisco, California, from October 31 - November 4. ANA598 is the Company's investigational hepatitis C non- nucleoside polymerase inhibitor.

ANA598 Phase I Study Results

In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed and fasted) and 3000 mg. In addition, a separate cohort received two 800 mg doses 12 hours apart. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study, although definitive conclusions regarding product safety and tolerability cannot be made until the results of future clinical trials of longer duration in more patients are known. All reported adverse events were classified as mild or moderate, with no apparent dose relationship and no pattern of events within any body system. The pharmacokinetic profile demonstrated sustained plasma levels of ANA598 with a half-life of 24 to 30 hours in the fasted state and 22 hours in the fed state, consistent with the potential for once-daily or twice-daily oral dosing. In the cohort that received two 800 mg
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... International Trade Commission (ITC) issued its final decision in the ... notice issued on December 23, the ITC ruled in favor ... was invalid. BMC President, James Xu ... with the ITC,s decision in this case. This victory for ... very beginning on the key patents in the case. ResMed ...
(Date:12/24/2014)... Dec. 23, 2014 PuraMed BioScience®, Inc., (OTC ... (OTC) medicinal and healthcare products, announced it received the ... a hemp-based, advanced headache relief product, for planned distribution ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel formulation ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... May 10, 2011 Cardica, Inc. (Nasdaq: CRDC ... and nine months ended March 31, 2011. Cardica,s management will ... to discuss the financial results and provide an update on ... diligently to bring our first anticipated commercial microcutter device, the ...
... 10, 2011 Cobalis Corp. (CLSC.PK) announced today they ... Allergy Defense Formula , on major national cable and ... featuring leading US allergist Dr. Paul H. Ratner, MD, ... allergies, giving seasonal and year-round sufferers the first truly ...
Cached Medicine Technology:Cardica Announces Fiscal 2011 Third Quarter Financial Results 2Cardica Announces Fiscal 2011 Third Quarter Financial Results 3Cardica Announces Fiscal 2011 Third Quarter Financial Results 4Cardica Announces Fiscal 2011 Third Quarter Financial Results 5Cardica Announces Fiscal 2011 Third Quarter Financial Results 6Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 2Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula 3
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... sick children with complex chronic illnesses can receive effective, less ... home," with easy access to a team of dedicated health ... likely to become seriously ill and need either hospitalization or ... at an enhanced medical home clinic at the University of ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... than can strike younger adults , , WEDNESDAY, March 11 ... test for quick diagnosis of a rare but potentially ... sudden death in young people. , The disease is ... flaw causes the muscle cells of one of the ...
... Stigmatize a Health FoodSAN FRANCISCO, March 11 Today ... verdict in a 2006 case which established that the ... occurring, and too insignificant to require warning labels. A ... Deputy Attorney General Sue Fiering argued that the labels ...
... HOUSTON, March 11 Salmonella bacteria research ... key elements of the bacteria,s disease-causing potential ... fight food-borne infections on Earth.(Logo: ... of food poisoning and related illnesses. According ...
... of Your Diabetes (TCOYD) conference and health fair will ... Center, bringing national and local medical experts in diabetes ... at risk for diabetes, and their loved ones for ... will discuss practical advice and developments in the treatment ...
... of the flu shot across the nation, has announced the availability ... ... 11, 2009-- Nationwide Medical/Surgical, a leading provider of the flu shot ... flu vaccine ., , ,The influenza virus, more commonly known as ...
... Grammy Award-winning singer advocates for research into disease ... Award-winning artist LeAnn Rimes shared her personal story ... psoriasis, and she encouraged lawmakers to support much-needed ... autoimmune disease."I was first diagnosed with psoriasis at ...
Cached Medicine News:Health News:New Test Seems to Spot Deadly Heart Condition 2Health News:New Test Seems to Spot Deadly Heart Condition 3Health News:Consumers Win Major Victory Over Seafood Scaremongers 2Health News:Space Research May Help Explain Salmonella Illness 2Health News:Space Research May Help Explain Salmonella Illness 3Health News:Taking Control of Your Diabetes Conference Returns to Hawaii to Bring Answers, Advocacy and Hope for People with Diabetes 2Health News:Nationwide Medical/Surgical Announces Preservative Free Flu Vaccine Available 2Health News:LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital 2Health News:LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital 3Health News:LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nation's Capital 4
Integrated electronics, three-chip CCD camera with PAL and NTSC output at 750 lines, RGB-video. 44mm x 49mm x 75mm, 180 grams....
Large image and wide-angle design....
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
PDA application listing specific ICD-9 coding listed in new Medicare National Coverage Determinations....
Medicine Products: